Aktuellt
SENASTE
Redeye is encouraged to learn that the first healthy volunteer has been dosed in the company’s phase Ia trial (n=60) with HER-096.The goal is to evaluate safety, tolerability, and blood-brain barrier penetration. In today’s release, the company reiterates its guidance that top-line data is to be expected before the end of 2023. We have seen the step back into the clinic as an important milestone and conclude that Herantis once again is a clinical-stage company. We reiterate our valuation for now and look forward to the results later this year.
LÄS MER
